Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to ...

The therapy in question is HPP737, a phosphodiesterase type 4 (PDE4) inhibitor that vTv has taken into phase 1 development to treat psoriasis. Newsoara originally secured the rights for the drug in ...

Virtual presentation scheduled for Thursday, February 26th at 12:40 PM ET Access the webcast hereCarlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) ...

There are currently no FDA-approved treatments for CIAS, a disabling feature of the disease that includes impaired attention, memory, and executive function. The Food and Drug Administration (FDA) has ...

Appointments strengthen Palisade Bio’s clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative ...

– ALTO-101 has been shown to positively impact cognition and key cognition-related EEG markers in humans when delivered orally – – Novel transdermal formulation of ALTO-101 exhibited favorable ...

Martin Kolb, MD, PhD, discusses the challenges of treating idiopathic pulmonary fibrosis (IPF) and highlights the potential benefits of a new PDE4B inhibitor, nerandomilast. Idiopathic pulmonary ...

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and ...

Palisade Bio Inc. has completed its analysis evaluating ex vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in ...

Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor ...